|
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes |
Apr 2023 |
The Oncologist |
Myelodysplastic Syndromes (MDS) |
|
Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria |
Jun 2023 |
Blood Advances |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria |
Mar 2021 |
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes |
Sep 2019 |
Clinical Cancer Research: an official Journal of the American Association of Cancer Research |
Myelodysplastic Syndromes (MDS) |
|
Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy |
Oct 2020 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria |
Mar 2024 |
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria |
Aug 2023 |
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Pitfalls in Assessing Response to Treatment in MDS |
Sep 2020 |
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Plain language summary of RACE study results: addition of eltrombopag to standard treatment of severe aplastic anemia |
Dec 2023 |
Immunotherapy |
Aplastic Anemia |
|
Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes |
Jul 2023 |
European Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
